Andrew Cheng
Patrimonio netto: 750 410 $ in data 30/06/2026
Patrimonio netto: 750 410 $ in data 30/06/2026
Andrew Cheng is currently an Independent Director at Vera Therapeutics, Inc. since 2017 and a Director at Boys & Girls Clubs of Metro Los Angeles.
Formerly, Dr. Cheng was President, Chief Executive Officer & Director at Akero Therapeutics, Inc. from 2018 to 2025; Independent Director at Arbutus Biopharma Corp.
from 2019 to 2022; Director at Syntimmune, Inc.; Director at Global Virus Network; Non-Executive Director at MorphoSys AG from 2022 to 2024; and Chief Medical Officer & Executive Vice President at Gilead Sciences, Inc. in 2018.
Education includes an undergraduate degree from The Johns Hopkins University in 1988 and a doctorate from Columbia University College of Physicians & Surgeons in 1996.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 21/05/2026 | 17.488 ( 0,02% ) | 750 410 $ | 30/06/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| VERA THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 01/05/2017 |
Boys & Girls Clubs of Metro Los Angeles
Boys & Girls Clubs of Metro Los Angeles Miscellaneous Commercial ServicesCommercial Services Operates as a Non-profit organization that provides proven programming services | Direttore/Membro del Consiglio | - |
| Società | Posizione | Fine |
|---|---|---|
| AKERO THERAPEUTICS, INC. | Amministratore Delegato | 09/12/2025 |
| MORPHOSYS AG | Direttore/Membro del Consiglio | 06/06/2024 |
| ARBUTUS BIOPHARMA CORPORATION | Direttore/Membro del Consiglio | 25/05/2022 |
| GILEAD SCIENCES, INC. | Direttore Tecnico/Scientifico/R&S | 07/09/2018 |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Engages in developing novel antibody therapies and severe toxicities in bio pharma industry | Direttore/Membro del Consiglio | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 10 |
|---|---|
Gilead Sciences, Inc.
Gilead Sciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes therapeutic products and treatments for life threatening diseases | Health Technology |
Arbutus Biopharma Corp.
Arbutus Biopharma Corp. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics which targets viral diseases | Health Technology |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Engages in developing novel antibody therapies and severe toxicities in bio pharma industry | Health Technology |
MorphoSys AG
MorphoSys AG BiotechnologyHealth Technology Manufactures pharmaceutical products and provides research and development services | Health Technology |
The Johns Hopkins University
The Johns Hopkins University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Global Virus Network
Global Virus Network Miscellaneous Commercial ServicesCommercial Services Researches on essential and critical defense against viral disease | Commercial Services |
Columbia University College of Physicians & Surgeons
Columbia University College of Physicians & Surgeons Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Akero Therapeutics, Inc.
Akero Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for patients with metabolic diseases | Health Technology |
Vera Therapeutics, Inc.
Vera Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical-stage biotechnology company, which focuses on development and treatments for immunological & inflammatory diseases | Health Technology |
Boys & Girls Clubs of Metro Los Angeles
Boys & Girls Clubs of Metro Los Angeles Miscellaneous Commercial ServicesCommercial Services Operates as a Non-profit organization that provides proven programming services | Commercial Services |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale